Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Results of a clinical study announced in New Orleans recently appeared to exonerate Avandia from long-held suspicions that the drug causes adverse cardiovascular events in patients undergoing treatment for diabetes 2. Many doctors and other critics, however, say that the study is flawed and remain unconvinced of the findings. Financial analysts believe the results will likely give GlaxoSmithKline’s one-time blockbuster drug a sales boost.

Read the rest of this entry »